Category: microbiome therapeutics

Seres Therapeutics microbiome drug flunks Phase 2 test in ulcerative colitis

BioPharma, biopharma nl, Cambridge, Clinical Trial, Daily, Erick Shaff, Massachusetts, microbiome therapeutics, Pharma, Seres Therapeutics, SYN, Top Story / July 22, 2021 July 22, 2021

Seres Therapeutics’ ambitions to treat ulcerative colitis with a microbiome drug were dealt a setback as its experimental therapy failed in Phase 2 testing. The company plans a “rigorous scientific analysis” to assess what happened and to determine the next steps for the program.

6th Microbiome Movement – Drug Development Summit

digital, drug development, Events, human disease, microbiome, microbiome biomarkers, microbiome therapeutics / February 24, 2021 February 24, 2021

Close the Clinical Gap, Discover the Next Generation of Microbiome-based Therapeutics, and Establish New Partnerships to Accelerate Your Research The most comprehensive forum for microbiome drug developers, the Microbiome Movement – Drug Development Summit returns for its sixth iteration! We will continue to unite forward-thinking researchers from the biopharmaceutical and academic communities to pursue the causal role of …

6th Microbiome Movement – Drug Development Summit Read More »

French startup lands $8.7M to advance microbiome therapies

ADM Ventures, Biocodex, BioPharma, Bpifrance, Celeste Management, Credit Mutuel Innovation, France, MaaT Pharma, microbiome therapeutics, News, Oncology, Seventure Partners, SkyViews Life Science, Startups, SymBiosis, ubiome / December 2, 2020 December 2, 2020

Founded in 2014, MaaT Pharma is pushing two therapies through clinical trials that are designed improve survival for patients with blood cancers and other diseases. Despite high-profile hiccups, the field of microbiome therapy remains attractive to investors.